Cabaletta Bio, Inc. Stock 12‑Month Price Target Raised to $14.71, Implies 427% UpsideTradingView·Aug 8 at 02:20 AMCABA-0.36%
Behind the Scenes of Jersey Mike's Blockbuster IPO and the Mid-Cap ShuffleGlobal Report·Aug 4 at 04:17 AMJMKE-1.31%CABA-0.36%
Surviving the Margins: How Niche Tech and Traditional Giants Are Navigating the 2026 Capital SqueezeGlobal Report·Jul 22 at 04:17 AMSRAD-0.52%EHGO0.00%
3 High-Risk, High-Reward Stocks to Buy Now for Strong Upside, According to AnalystsTip Ranks·Jul 10 at 02:48 PMONT+5.60%NNE+4.36%
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 CongressUnusual Whales·Jun 3 at 06:01 AMCABA-0.36%
Analyst Reiterates Buy on Cabaletta Bio, Citing Strong Non-Preconditioned PV Data, Scalable Manufacturing, and Multiple Upcoming CatalystsTip Ranks·May 14 at 02:15 PMCABA-0.36%LABU+0.23%
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update | CABA Stock NewsStockTitan·May 13 at 10:05 PMCABA-0.36%XBI+0.03%
U.S. stock night market fluctuations: Cabaletta Bio rose 7.57% in the night market, boosted by a combination of $150 million financing and positive clinical data, driving the stock price surgePrice Alert·May 5 at 02:36 AMCABA-0.36%
Cabaletta Bio Maintained at Buy as Emerging Rese-cel Data Support Preconditioning-Free Potential; $13 Price Target ReaffirmedTip Ranks·May 4 at 08:35 PMCABA-0.36%FBT+0.05%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·May 4 at 12:06 PMCNSP+7.21%MNDR+4.00%
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Mondaybenzinga_article·May 4 at 08:54 AMCELC-2.95%GBTG-0.11%
